| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
L-theanine, also known as L-glutamic acid γ-ethylamide, prevents extracellular glutamine from entering neurons, which in turn prevents glutamate from being released exocytotically [3]. L-theanine (500 μM; 72 hours) raises glutathione levels in astrocytes and inhibits neuronal death brought on by excess dopamine [3]. Glutathione synthesis involves L-theanine (0–5 mM; 72 hours) [3]. Melanoma cells' viability is dose-dependently inhibited by L-theanine (0.1–5 mM; 24 hours), but not that of normal epidermal melanocytes [4]. In A375 cells, L-theanine (1–5 mM; 24 hours) causes apoptosis, suppresses cell migration, and stops the cell cycle in the G0/G1 phase [4]. Additionally, B16–F10 melanoma cells' migration, apoptosis, and proliferation are impacted by L-theanine (1–5 mM; 24 hours) [4]. By blocking mitochondria-mediated processes and lowering ROS generation, L-theanine prevents cadmium-induced PC12 cell apoptosis [5].
|
|---|---|
| ln Vivo |
In the striatum of normal mice, L-theanine (4.0 mg/kg; oral; once daily for 14 days) increases the glutathione concentration [3].
|
| Cell Assay |
Cell proliferation assay [4]
Cell Types: A375 and PIG1 Cell Tested Concentrations: 0.1, 0.5, 1, 2 and 5 mM Incubation Duration: 24 hrs (hours) Experimental Results: The viability of A375 cells diminished in a dose-dependent manner, but that of PIG1 cells did not. Cell cycle analysis [4] Cell Types: A375 Tested Concentrations: 1, 2 and 5 mM Incubation Duration: 24 hrs (hours) Experimental Results: Causes dose-dependent accumulation of A375 cells in G0/G1 phase and prevents cells from entering S phase. Western Blot Analysis[4] Cell Types: A375 Tested Concentrations: 1, 2 and 5 mM Incubation Duration: 24 h Experimental Results: Remarkably diminished the expression of proliferating cell nuclear antigen (PCNA), diminished protein levels of cyclinD1, cyclinE1, and cyclin-dependent protein kinase (CDK2 and CDK4). Potentiated the expression of cyclin-dependent kinase inhibitor 1A (CDKN1A, p21). Dose-dependently increased the levels of apoptosis-promoting proteins including BAX and cleaved-caspase3 and diminished the level of antiapoptotic protein BCL-2. Concentration dependently diminished the protein levels of ICAM-1, VCAM-1, MMP9, and MMP2. Dose-dependently increased the p53 expression. |
| Animal Protocol |
Animal/Disease Models: Healthy male ICR mice, body weight 32-34 grams [3]
Doses: 4.0 mg/kg Route of Administration: Orally, one time/day for 14 days Experimental Results: Glutathione content in the striatum increased Dramatically, but Glutathione levels were not increased in the midbrain. |
| References |
[1]. Vuong QV, et al. L-Theanine: properties, synthesis and isolation from tea. J Sci Food Agric. 2011 Aug 30;91(11):1931-9.
[2]. Kimura K, et al. L-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007 Jan;74(1):39-45. [3]. Takeshima M, et al. l-Theanine protects against excess dopamine-induced neurotoxicity in the presence of astrocytes. J Clin Biochem Nutr. 2016 Sep;59(2):93-99. [4]. Zhang R, et al. L-Theanine inhibits melanoma cell growth and migration via regulating expression of the clock gene BMAL1. Eur J Nutr. 2022 Mar;61(2):763-777. [5]. Ben P, et al. Protective Effect of L-Theanine on Cadmium-Induced Apoptosis in PC12 Cells by Inhibiting the Mitochondria-Mediated Pathway. Neurochem Res. 2015 Aug;40(8):1661-70. |
| Molecular Formula |
C7H14N2O3
|
|---|---|
| Molecular Weight |
174.1977
|
| CAS # |
3081-61-6
|
| Related CAS # |
L-Theanine-d5;1217451-85-8
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
O=C(C([H])([H])C([H])([H])[C@@]([H])(C(=O)O[H])N([H])[H])N([H])C([H])([H])C([H])([H])[H]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~150 mg/mL (~861.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (574.05 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.7405 mL | 28.7026 mL | 57.4053 mL | |
| 5 mM | 1.1481 mL | 5.7405 mL | 11.4811 mL | |
| 10 mM | 0.5741 mL | 2.8703 mL | 5.7405 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
